Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APRIORI: FOLFOXIRI/Bevacizumab for Not Optimally Resectable Liver/Lung Metastases From Colorectal Carcinoma
NCT01126866Phase 2Terminated
- Sponsor
- National Center for Tumor Diseases
- Start
- Jun 2009
- Primary completion
- Mar 2011
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, fluorouracil, folinic acid, oxaliplatin and irinotecan in colorectal carcinoma (CRC), sponsored by National Center for Tumor Diseases. Primary endpoint: Surgically complete resectability at 12 months. Started Jun 2009; status: terminated.
02
Drugs
bevacizumabfluorouracilfolinic acidoxaliplatinirinotecan
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT01126866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01126866.